Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

KalVista Pharmaceuticals (KALV) Profit After Tax: 2013-2025

Historic Profit After Tax for KalVista Pharmaceuticals (KALV) over the last 13 years, with Apr 2025 value amounting to -$183.4 million.

  • KalVista Pharmaceuticals' Profit After Tax rose 5.34% to -$42.3 million in Q2 2025 from the same period last year, while for Apr 2025 it was -$156.4 million, marking a year-over-year decrease of 74.63%. This contributed to the annual value of -$183.4 million for FY2025, which is 44.85% down from last year.
  • Latest data reveals that KalVista Pharmaceuticals reported Profit After Tax of -$183.4 million as of FY2025, which was down 44.85% from -$126.6 million recorded in FY2024.
  • KalVista Pharmaceuticals' Profit After Tax's 5-year high stood at -$46.2 million during FY2021, with a 5-year trough of -$183.4 million in FY2025.
  • In the last 3 years, KalVista Pharmaceuticals' Profit After Tax had a median value of -$126.6 million in 2024 and averaged -$134.3 million.
  • Data for KalVista Pharmaceuticals' Profit After Tax shows a maximum YoY slumped of 78.05% (in 2022) over the last 5 years.
  • Yearly analysis of 5 years shows KalVista Pharmaceuticals' Profit After Tax stood at -$46.2 million in 2021, then slumped by 78.05% to -$82.3 million in 2022, then decreased by 12.83% to -$92.9 million in 2023, then crashed by 36.31% to -$126.6 million in 2024, then plummeted by 44.85% to -$183.4 million in 2025.